A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Key facts

Sponsor

BeiGene

Principal Investigator

Study Director

BeiGene

Intervention

BGB-A445(drug)

Enrollment

113 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (18)

• Beijing Cancer Hospital, Beijing, Beijing Municipality, China
• Fujian Cancer Hospital, Fuzhou, Fujian, China
• The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China
• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
• The Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi, China
• The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
• Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
• The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
• Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
• The First Hospital of Jilin University, Changchun, Jilin, China
• Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
• Shandong Cancer Hospital, Jinan, Shandong, China
• Jining No1 Peoples Hospital West Branch, Jining, Shandong, China
• Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
• +3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant melanoma of the mucosa

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06797297
  A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
  Innovent Biologics (Suzhou) Co. Ltd.
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05089370
  Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
  University of Colorado, Denver
• RECRUITINGPHASE2NCT04879654
  Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery
  Eye & ENT Hospital of Fudan University

See all trials for Malignant melanoma of the mucosa →